Kamada Cash Flow Conversion Efficiency
Kamada cash flow conversion efficiency. Based on the latest financial reports, Kamada (KMDA) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA10.42 Million ≈ $27.92K USD) by net assets (ILA265.23 Million ≈ $711.08K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Kamada (2007–2024)
Cash flow conversion efficiency of Kamada from 2007 to 2024. This chart illustrates how Kamada's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Kamada for real-time trading data and today's change.
Kamada Cash Flow Conversion Ratio Explained
Kamada cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kamada Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kamada ranked by their cash flow conversion efficiency. Also see Kamada (KMDA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Source Capital Closed Fund
NYSE:SOR
|
-0.093x |
|
Pareto Bank ASA
OL:PARB
|
-0.015x |
|
Hamborner REIT AG
XETRA:HABA
|
0.031x |
|
Shaanxi Jinye Science Technology and Education Group Co Ltd
SHE:000812
|
0.148x |
|
Sino-Argi Leading Biosciences
SHG:603970
|
-0.219x |
|
Polyplex (Thailand) Public Company Limited
BK:PTL
|
0.003x |
|
Trilogy Metals Inc
TO:TMQ
|
-0.009x |
|
ElringKlinger AG
F:ZIL2
|
0.233x |
Annual Cash Flow Conversion Efficiency for Kamada (2007–2024)
The table below shows the annual cash flow conversion efficiency of Kamada from 2007 to 2024. Review Kamada free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA259.46 Million ≈ $695.61K |
ILA47.59 Million ≈ $127.60K |
0.183x | +937.34% |
| 2023-12-31 | ILA244.02 Million ≈ $654.21K |
ILA4.32 Million ≈ $11.57K |
0.018x | -89.11% |
| 2022-12-31 | ILA176.02 Million ≈ $471.90K |
ILA28.59 Million ≈ $76.64K |
0.162x | +425.62% |
| 2021-12-31 | ILA176.82 Million ≈ $474.06K |
ILA-8.82 Million ≈ $-23.64K |
-0.050x | -146.63% |
| 2020-12-31 | ILA178.64 Million ≈ $478.92K |
ILA19.11 Million ≈ $51.22K |
0.107x | -47.51% |
| 2019-12-31 | ILA135.32 Million ≈ $362.79K |
ILA27.57 Million ≈ $73.92K |
0.204x | +117.11% |
| 2018-12-31 | ILA112.38 Million ≈ $301.28K |
ILA10.55 Million ≈ $28.27K |
0.094x | +115.90% |
| 2017-12-31 | ILA89.49 Million ≈ $239.92K |
ILA3.89 Million ≈ $10.43K |
0.043x | +52.93% |
| 2016-12-31 | ILA66.74 Million ≈ $178.94K |
ILA1.90 Million ≈ $5.09K |
0.028x | +114.74% |
| 2015-12-31 | ILA72.51 Million ≈ $194.39K |
ILA-13.98 Million ≈ $-37.48K |
-0.193x | -57.44% |
| 2014-12-31 | ILA80.99 Million ≈ $217.14K |
ILA-9.92 Million ≈ $-26.59K |
-0.122x | -185.86% |
| 2013-12-31 | ILA89.97 Million ≈ $241.21K |
ILA-3.85 Million ≈ $-10.33K |
-0.043x | +85.28% |
| 2012-12-31 | ILA28.39 Million ≈ $76.12K |
ILA-8.26 Million ≈ $-22.15K |
-0.291x | -801.65% |
| 2011-12-31 | ILA22.67 Million ≈ $60.79K |
ILA940.36K ≈ $2.52K |
0.041x | -89.67% |
| 2010-12-31 | ILA26.49 Million ≈ $71.01K |
ILA10.63 Million ≈ $28.50K |
0.401x | +192.43% |
| 2009-12-31 | ILA30.15 Million ≈ $80.83K |
ILA-13.09 Million ≈ $-35.10K |
-0.434x | +56.84% |
| 2008-12-31 | ILA12.64 Million ≈ $33.89K |
ILA-12.72 Million ≈ $-34.11K |
-1.006x | -456.76% |
| 2007-12-31 | ILA69.57 Million ≈ $186.51K |
ILA-12.57 Million ≈ $-33.71K |
-0.181x | -- |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more